Aliases & Classifications for Motion Sickness

MalaCards integrated aliases for Motion Sickness:

Name: Motion Sickness 57 12 25 43 44 15 73
Airsickness 25 73
Carsickness 25 73
Seasickness 25 73
Travel Sickness 12
Riders' Vertigo 25

Characteristics:

OMIM:

57
Inheritance:
not likely mendelian, but shows familial aggregation


Classifications:



External Ids:

OMIM 57 158280
Disease Ontology 12 DOID:2951
ICD10 33 T75.3
ICD9CM 35 994.6
MeSH 44 D009041
NCIt 50 C34824
MedGen 42 C0026603
SNOMED-CT via HPO 69 88425004

Summaries for Motion Sickness

MedlinePlus : 43 Motion sickness is a common problem in people traveling by car, train, airplanes, and especially boats. Anyone can get it, but it is more common in children, pregnant women, and people taking certain medicines. Motion sickness can start suddenly, with a queasy feeling and cold sweats. It can then lead to dizziness and nausea and vomiting. Your brain senses movement by getting signals from your inner ears, eyes, muscles, and joints. When it gets signals that do not match, you can get motion sickness. For example, if you are reading on your phone while riding a bus, your eyes are focused on something that is not moving, but your inner ear senses motion. Where you sit can make a difference. The front seat of a car, forward cars of a train, upper deck on a boat or wing seats in a plane may give you a smoother ride. Looking out into the distance - instead of trying to read or look at something in the vehicle - can also help. Centers for Disease Control and Prevention

MalaCards based summary : Motion Sickness, also known as airsickness, is related to space motion sickness and migraine with or without aura 1, and has symptoms including vomiting alone, abdominal pain and asthenia. An important gene associated with Motion Sickness is HTR3A (5-Hydroxytryptamine Receptor 3A), and among its related pathways/superpathways are Monoamine GPCRs and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Histamine and Diphenhydramine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and skin, and related phenotypes are abnormality of the nervous system and Increased transferrin (TF) endocytosis

Genetics Home Reference : 25 Motion sickness is a common condition characterized by a feeling of unwellness brought on by certain kinds of movement. The usual symptoms include dizziness, pale skin (pallor), and sweating, followed by nausea and vomiting. Affected individuals may also experience rapid breathing (hyperventilation), headache, restlessness, and drowsiness. These symptoms can be triggered by many kinds of motion, particularly traveling in a car, bus, train, airplane, or boat. Amusement park rides, skiing, and virtual reality environments can also induce motion sickness.

Wikipedia : 76 Motion sickness is a condition in which a disagreement exists between visually perceived movement and... more...

Description from OMIM: 158280

Related Diseases for Motion Sickness

Diseases related to Motion Sickness via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Related Disease Score Top Affiliating Genes
1 space motion sickness 33.8 AVP TANC1
2 migraine with or without aura 1 28.0 FOS HTR1A HTR3A HTR7 TAC1
3 social phobia 10.6 HTR1A HTR3A
4 premature ejaculation 10.6 HTR1A HTR3A
5 psychosexual disorder 10.5 HTR1A HTR7
6 kleptomania 10.5 HTR1A HTR7
7 functional gastric disease 10.4 HTR3A HTR7
8 inappropriate adh syndrome 10.3 AQP1 AVP
9 central pontine myelinolysis 10.3 AQP1 AVP
10 intermittent explosive disorder 10.3 HTR1A HTR7
11 dyspepsia 10.3 HTR1A HTR3A
12 superior mesenteric artery syndrome 10.3 AVP HTR3A
13 impaired renal function disease 10.3 AQP1 AVP
14 rumination disorder 10.2 HTR1A HTR3A HTR7
15 mental depression 10.2 HTR1A HTR7
16 brunner syndrome 10.2 HTR1A HTR3A HTR7
17 withdrawal disorder 10.2 FOS HTR7
18 neuronitis 10.2
19 aging 10.1
20 drug-induced mental disorder 10.0 FOS HTR1A HTR7
21 drug psychosis 10.0 FOS HTR1A HTR7
22 disease of mental health 10.0 FOS HTR1A HTR7
23 yaws 10.0
24 alcohol dependence 10.0 HTR1A HTR3A HTR7
25 serotonin syndrome 9.9 HTR1A HTR3A TAC1
26 generalized anxiety disorder 9.9 HTR1A HTR3A
27 scoliosis 9.9
28 idiopathic scoliosis 9.9
29 syncope 9.9
30 functional diarrhea 9.8 HTR3A HTR7 TAC1
31 diabetes insipidus, nephrogenic, autosomal 9.8 AQP1 AVP
32 irritable bowel syndrome 9.8 HTR3A HTR7 TAC1
33 meniere disease 9.8 AQP1 FAM136A
34 thiourea tasting 9.7
35 helicobacter pylori infection 9.7
36 orthostatic intolerance 9.7
37 anxiety 9.7
38 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.7
39 spinal cord injury 9.7
40 thrombosis 9.7
41 cervicitis 9.7
42 plague 9.7
43 retinitis 9.7
44 hyperglycemia 9.7
45 retinal degeneration 9.7
46 mal de debarquement syndrome 9.7
47 headache 9.7
48 hypoxia 9.7
49 amnestic disorder 9.7 FOS HTR1A HTR3A HTR7
50 peripheral vertigo 9.6 AVP FAM136A

Graphical network of the top 20 diseases related to Motion Sickness:



Diseases related to Motion Sickness

Symptoms & Phenotypes for Motion Sickness

Symptoms via clinical synopsis from OMIM:

57
Neuro:
motion sickness


Clinical features from OMIM:

158280

Human phenotypes related to Motion Sickness:

32
# Description HPO Frequency HPO Source Accession
1 abnormality of the nervous system 32 HP:0000707

UMLS symptoms related to Motion Sickness:


vomiting alone, abdominal pain, asthenia, body temperature changes, chest pain, constipation, coughing, cyanosis, diarrhea, dyspepsia, edema, eye manifestations, fatigue, fever, halitosis, headache, heartburn, icterus, nausea and vomiting, oral manifestations, pain, pelvic pain, pruritus, sciatica, signs and symptoms, signs and symptoms, digestive, signs and symptoms, respiratory, skin manifestations, syncope, vertigo, chills, polydipsia, chronic pain, renal colic, vertigo/dizziness, gastrointestinal gas, hot flushes, urological manifestations, symptoms, mobility limitation, prodromal symptoms, hypertriglyceridemic waist, medically unexplained symptoms, nausea

GenomeRNAi Phenotypes related to Motion Sickness according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased transferrin (TF) endocytosis GR00363-A 9.23 ADRA2A AVP FOS HTR1A HTR3A HTR7

MGI Mouse Phenotypes related to Motion Sickness:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.81 ADRA2A AQP1 AVP FOS HTR1A HTR3A
2 mortality/aging MP:0010768 9.56 ADRA2A AQP1 AVP EXT2 FOS HTR1A
3 nervous system MP:0003631 9.23 HTR7 TANC1 ADRA2A AQP1 AVP FOS

Drugs & Therapeutics for Motion Sickness

Drugs for Motion Sickness (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 75614-87-8, 51-45-6 774
2
Diphenhydramine Approved, Investigational Phase 4,Not Applicable 147-24-0, 58-73-1 3100
3
Promethazine Approved, Investigational Phase 4,Not Applicable 60-87-7 4927
4
Aprepitant Approved, Investigational Phase 4 170729-80-3 151165 6918365
5
Fosaprepitant Approved Phase 4 172673-20-0 219090
6
Ondansetron Approved Phase 4,Not Applicable 99614-02-5 4595
7
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
8
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
9
Meclizine Approved Phase 4,Phase 2,Phase 1 569-65-3 4034
10
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
11
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
12
Racepinephrine Approved Phase 4 329-65-7 838
13
Substance P Investigational Phase 4 33507-63-0 44359816
14 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
15 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
16 Histamine Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
17 Histamine H1 Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
18
Histamine Phosphate Phase 4,Phase 2,Phase 1,Not Applicable 51-74-1 65513
19 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
20 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
21 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
22 Adjuvants, Anesthesia Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
23 Bromides Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
24 Butylscopolammonium Bromide Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
25 Cholinergic Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
26 Muscarinic Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
27 Mydriatics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
28 Parasympatholytics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
29 Scopolamine hydrobromide Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 114-49-8
30 Anesthetics, Local Phase 4,Not Applicable
31 Anti-Allergic Agents Phase 4,Phase 2,Phase 1,Not Applicable
32 Antiemetics Phase 4,Phase 2,Phase 1,Not Applicable
33 Antipruritics Phase 4,Not Applicable
34 Central Nervous System Depressants Phase 4,Not Applicable
35 Dermatologic Agents Phase 4,Not Applicable
36 Gastrointestinal Agents Phase 4,Phase 2,Phase 1,Not Applicable
37 Hypnotics and Sedatives Phase 4,Not Applicable
38 Anti-Anxiety Agents Phase 4,Not Applicable
39 Antipsychotic Agents Phase 4,Not Applicable
40 neurokinin A Phase 4
41 Neurokinin-1 Receptor Antagonists Phase 4
42 Psychotropic Drugs Phase 4,Not Applicable
43 Serotonin Agents Phase 4,Not Applicable
44 Serotonin Antagonists Phase 4,Not Applicable
45 Tranquilizing Agents Phase 4,Not Applicable
46 Cholinesterase Inhibitors Phase 4,Not Applicable
47 Epinephryl borate Phase 4
48 glucagon Phase 4
49 Glucagon-Like Peptide 1 Phase 4
50 Hormone Antagonists Phase 4

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 Countermeasures to Reduce Sensorimotor Impairment and Space Motion Sickness Resulting From Altered Gravity Levels Completed NCT02136420 Phase 4 Promethazine;Placebo
2 The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and Vomiting Completed NCT01897337 Phase 4 Aprepitant;placebo
3 Comparison of the Effects of Neostigmine With Sugammadex on Postoperative Nausea and Vomiting. Completed NCT02286752 Phase 4 Neostigmine;sugammadex
4 Motion Sickness Medications and Vestibular Time Constant Recruiting NCT03270839 Phase 4 Bonine 25Mg Chewable Tablet;Kwells;Placebo Oral Tablet
5 A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects Terminated NCT02802514 Phase 4 Albiglutide 50mg;Albiglutide matching placebo;Exenatide 10microgram;Exenatide placebo (saline)
6 Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria Completed NCT00785135 Phase 3
7 Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray Terminated NCT02155309 Phase 2, Phase 3 Scopolamine;Placebo
8 Levo Phencynonate Hydrochloride for the Prevention of Seasickness Completed NCT02241629 Phase 2 placebo;levo phencynonate hydrochloride
9 Effects of Transdermal Scopolamine on Occupational Performance Completed NCT00374478 Phase 2 Scopolamine
10 Meclizine as a Potential Smoking Cessation Treatment Completed NCT01443858 Phase 2 Meclizine;Nicotine Patch;Placebo
11 Phase II Dose-ranging Study of APD421 in PONV Completed NCT01510704 Phase 2 APD421;Placebo
12 Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV) Completed NCT00895830 Phase 2 APD405;Placebo
13 4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine Not yet recruiting NCT03578354 Phase 2 4-aminopyridine;Atenolol
14 A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants. Completed NCT02839135 Phase 1 Reformulated scopolamine patch;Marketed scopolamine patch
15 Meclizine for Hepatocellular Carcinoma Recruiting NCT03253289 Phase 1 Meclizine Oral Tablet
16 A Double-blind Comparison of Scopolamine With Cinnarizin for Prevention of Simulator Sickness Unknown status NCT01198106 Not Applicable scopolamine;cinnarizine
17 Parabolic Flight Induced Neuroplasticity Studied With Advanced Magnetic Resonance Imaging Methods Unknown status NCT02517216 Not Applicable
18 Influence of Gravity on the Perception of Egocentric Distance (Blindpulling) Unknown status NCT02508545 Not Applicable
19 Effects of Inverted Vision on Pointing and Grasping in Parabolic Flight Unknown status NCT02885844 Not Applicable
20 Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines? Completed NCT00360282 Not Applicable Rizatriptan
21 Effect of Transcutaneous Vagal Nerve Stimulation on Reducing Visually Induced Motion Sickness in Healthy Volunteers Completed NCT02177890 Not Applicable
22 Study of Hierarchy of Afferents in Postural Control of Children With Dyslexia Completed NCT02879786 Not Applicable
23 Risk Factors for Post Operative Nausea and Vomiting(PONV) in Patients Underwent Gynecological Operation Under General Anesthesia Completed NCT01020201
24 Assessment of Cholinergic and Cognitive Function Using Pharmacologic ASL-Perfusion MRI Completed NCT01379001 Not Applicable Scopolamine;Placebo;Donepezil
25 Anti Emetic Efficacy of Combination of Ramosetron and Premixture of Naloxone With Patient-controlled Analgesia Completed NCT02416115 Not Applicable Ramosetron;Naloxone;saline;Morphine
26 Virtual Reality Distraction for Procedural Pain Management and Anxiety in Children With Burn Injuries : A Pilot Study Completed NCT02794103 Not Applicable
27 Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin Completed NCT00729677
28 Influence of Couch Tracking Motion Completed NCT02820532 Not Applicable
29 Research on Quantification of VR(Virtual Reality) Related Stress and Relaxation Recruiting NCT02986555 Not Applicable
30 Evaluation and Characterization of Motion Sickness on Passengers Sailing on the Astrolabe Recruiting NCT02911402
31 Risk Factors for Postoperative Nausea, Vomiting and Pruritus Recruiting NCT03178058
32 3-dimensional Versus 2-dimensional Laparoscopy of Ovarian Cyst Recruiting NCT03453333 Not Applicable
33 Virtual Reality in Labor and Delivery for Reduction in Pain Recruiting NCT03437031 Not Applicable
34 Transcranial Electrical Stimulation for Mal de Debarquement Syndrome Recruiting NCT02540616 Not Applicable
35 Transcranial Magnetic Stimulation for Mal de Debarquement Syndrome Recruiting NCT02470377 Not Applicable
36 The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression Recruiting NCT02849639 Early Phase 1 Scopolamine patch
37 Predictive Progressive Factors of Adolescent Idiopathic Scoliosis Recruiting NCT02862392
38 Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients Not yet recruiting NCT03560583 Not Applicable Metoclopramide;Placebo Oral Tablet
39 The Effect of Gum Chewing on Postoperative Ileus Withdrawn NCT00879294 Not Applicable
40 Intraoperative Electronic Reminder Module to Enhance Postoperative Nausea and Vomiting Prophylaxis Withdrawn NCT02830412 Not Applicable
41 Rescue Emetic Therapy for Children Having Elective Surgery Withdrawn NCT01067677 Not Applicable Metaclopramide;Ondansetron;diphenhydramine;Saline

Search NIH Clinical Center for Motion Sickness

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: motion sickness

Genetic Tests for Motion Sickness

Anatomical Context for Motion Sickness

MalaCards organs/tissues related to Motion Sickness:

41
Brain, Eye, Skin, Heart, Testes, Liver, Amygdala

Publications for Motion Sickness

Articles related to Motion Sickness:

(show top 50) (show all 647)
# Title Authors Year
1
Effects of unexpected visual motion on postural sway and motion sickness. ( 29764619 )
2018
2
Predicting vection and visually induced motion sickness based on spontaneous postural activity. ( 29181555 )
2018
3
Assessment of Olfactory Perception in Individuals with Motion Sickness. ( 29673427 )
2018
4
Postural time-to-contact as a precursor of visually induced motion sickness. ( 29589080 )
2018
5
Effect of Prophylactic Medication on Associated Dizziness and Motion Sickness in Migraine. ( 29227453 )
2018
6
Visual Occlusion Decreases Motion Sickness in a Flight Simulator. ( 29490570 )
2018
7
Acupuncture relieves motion sickness via the IRI^-ERK1/2-dependent insulin receptor signalling pathway. ( 29436382 )
2018
8
Reduction of Motion Sickness Through Targeting Histamine<i>N</i>-Methyltransferase in the Dorsal Vagal Complex of the Brain. ( 29298819 )
2018
9
Virtual reality sickness questionnaire (VRSQ): Motion sickness measurement index in a virtual reality environment. ( 29477332 )
2018
10
The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance &amp;amp; cognitive function. ( 29522648 )
2018
11
Allocating less attention to central vision during vection is correlated with less motion sickness. ( 29325490 )
2018
12
Intravestibular Balance and Motion Sickness. ( 29463358 )
2018
13
Relationship between motion sickness susceptibility and vestibulo-ocular reflex gain and phase. ( 29689763 )
2018
14
Higher Asymmetry Ratio and Refixation Saccades in Individuals with Motion Sickness. ( 29401064 )
2018
15
Passive restraint reduces visually induced motion sickness in older adults. ( 28150962 )
2017
16
Electroacupuncture Could Reduce Motion Sickness Susceptibility in Healthy Male Adults: A Double-Blinded Study. ( 29279732 )
2017
17
Orientation Preferences and Motion Sickness Induced in a Virtual Reality Environment. ( 28923138 )
2017
18
Determinants of Motion Sickness in Tilting Trains: Coriolis/Cross-Coupling Stimuli and Tilt Delay. ( 28555125 )
2017
19
The efficacy of airflow and seat vibration on reducing visually induced motion sickness. ( 28634889 )
2017
20
Motion sickness increases functional connectivity between visual motion and nausea-associated brain regions. ( 28245927 )
2017
21
Effects of Physical Driving Experience on Body Movement and Motion Sickness During Virtual Driving. ( 29046173 )
2017
22
Effects of decades of physical driving on body movement and motion sickness during virtual driving. ( 29121059 )
2017
23
Sex and Age Differences in Motion Sickness in Rats: The Correlation with Blood Hormone Responses and Neuronal Activation in the Vestibular and Autonomic Nuclei. ( 28261089 )
2017
24
A Historical View of Motion Sickness-A Plague at Sea and on Land, Also with Military Impact. ( 28421029 )
2017
25
Brain Activation by H1 Antihistamines Challenges Conventional View of Their Mechanism of Action in Motion Sickness: A Behavioral, c-Fos and Physiological Study in Suncus murinus (House Musk Shrew). ( 28659825 )
2017
26
Low level of swiprosin-1/EFhd2 in vestibular nuclei of spontaneously hypersensitive motion sickness mice. ( 28128226 )
2017
27
Correlations between individual susceptibility to visually induced motion sickness and decaying time constant of after-nystagmus. ( 28502398 )
2017
28
Prevalence, Predictors, and Prevention of Motion Sickness in Zero-G Parabolic Flights. ( 28061915 )
2017
29
Effect of exposure to short-wavelength light on susceptibility to motion sickness. ( 28538515 )
2017
30
History of High Motion Sickness Susceptibility Predicts Vestibular Dysfunction Following Sport/Recreation-Related Concussion. ( 29189336 )
2017
31
Vection is the main contributor to motion sickness induced by visual yaw rotation: Implications for conflict and eye movement theories. ( 28380077 )
2017
32
Cross-coupling vestibular stimulation: motion sickness and the vestibulo-sympathetic reflex. ( 28455665 )
2017
33
Storage of passive motion pattern in hippocampal CA1 region depends on CaMKII/CREB signaling pathway in a motion sickness rodent model. ( 28230177 )
2017
34
Evaluation of Motion Sickness Induced by 3D Video Clips. ( 26832611 )
2016
35
Contribution of intra-vestibular sensory conflict to motion sickness and dizziness in migraine disorders. ( 27385797 )
2016
36
Motion sickness and sopite syndrome associated with parabolic flights: a case report. ( 26624575 )
2016
37
Psychometric Properties of the Greek Version of the Gianaros Motion Sickness Assessment Questionnaire. ( 27779955 )
2016
38
Motion sickness in ancient China: Seasickness and cart-sickness. ( 27432177 )
2016
39
Motion sickness. ( 27638085 )
2016
40
Biodynamic Hypothesis for the Frequency Tuning of Motion Sickness. ( 26735236 )
2016
41
Vestibular evoked myogenic potentials and motion sickness medications. ( 27178852 )
2016
42
The virtual reality head-mounted display Oculus Rift induces motion sickness and is sexist in its effects. ( 27915367 )
2016
43
Moving in a Moving World: A Review on Vestibular Motion Sickness. ( 26913019 )
2016
44
Motion Sickness and Resting Energy Expenditure in Chinese Male Adults. ( 27026119 )
2016
45
Motion Sickness Prediction in Aeromedical Evacuation of Patients with Ebola. ( 26735238 )
2016
46
Meniere's, migraine, and motion sickness. ( 27918236 )
2016
47
The influence of sleep deprivation and oscillating motion on sleepiness, motion sickness, and cognitive and motor performance. ( 27641791 )
2016
48
EEG Alpha and Gamma Modulators Mediate Motion Sickness-Related Spectral Responses. ( 26790485 )
2016
49
Subjective Vertical Conflict Theory and Space Motion Sickness. ( 26802378 )
2016
50
Effects of naloxone on motion sickness in cats alone and with broad spectrum antiemetics. ( 27615675 )
2016

Variations for Motion Sickness

Expression for Motion Sickness

Search GEO for disease gene expression data for Motion Sickness.

Pathways for Motion Sickness

GO Terms for Motion Sickness

Cellular components related to Motion Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.35 ADRA2A AQP1 HTR1A HTR3A HTR7
2 dendrite GO:0030425 8.92 AVP HTR1A HTR7 TANC1

Biological processes related to Motion Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.93 ADRA2A AVP EXT2 HTR1A HTR3A HTR7
2 G-protein coupled receptor signaling pathway GO:0007186 9.8 ADRA2A AVP HTR1A HTR7 TAC1
3 chemical synaptic transmission GO:0007268 9.56 HTR1A HTR3A HTR7 TAC1
4 cellular response to hormone stimulus GO:0032870 9.48 ADRA2A FOS
5 renal water homeostasis GO:0003091 9.43 AQP1 AVP
6 water transport GO:0006833 9.37 AQP1 AVP
7 multicellular organismal water homeostasis GO:0050891 9.32 AQP1 AVP
8 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.16 HTR1A HTR7
9 positive regulation of saliva secretion GO:0046878 8.96 AQP1 TAC1
10 vasoconstriction GO:0042310 8.8 AVP HTR1A HTR7

Molecular functions related to Motion Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neurotransmitter receptor activity GO:0030594 9.16 HTR1A HTR7
2 G-protein coupled serotonin receptor activity GO:0004993 8.96 HTR1A HTR7
3 serotonin binding GO:0051378 8.8 HTR1A HTR3A HTR7

Sources for Motion Sickness

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....